Day: September 5, 2024

Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series 

Abstract Objective Combination biological therapies are being considered increasingly for patients with multiple co-morbidities requiring biologics. There are limited data available on this approach, and concerns remain about the possible risk of adverse events, particularly infection. Methods We present three patients on dual biologics for rheumatic disease and asthma. The biologic combinations used were etanercept and mepolizumab, infliximab and omalizumab, and etanercept and omalizumab. The time on combination biologic therapies ranged from 24 to 36 months. Patients were monitored for any serious adverse events. Results All three patients were able to tolerate combined biologic therapies, with no serious adverse events. All

reporting ADR – Adverse Drug Reaction Reporting

National Pharmacovigilance Centre, DRAP collects reports of suspected Adverse Events associated with the use of therapeutic products. Anyone can report a suspected adverse events. DRAP has enabled both electronic and manual systems for collection of reports of suspected adverse events:- LEARNING OBJECTIVES Define an adverse drug reaction. Discuss the detection of adverse drug reactions. Discuss the assessment of adverse drug reactions. WHAT HAPPENS TO THE REPORT? Your report matters. Together, letus save lives through vigilant reporting.

Antibiotic therapy for multidrug-resistant nosocomial infections (Pseudomonas spp., Acinetobacter spp., and Enterobacteriaceae)

Multidrug-Resistant Acinetobacter spp.: Increasingly Problematic Nosocomial Pathogens Kyungwon Lee, Dongeun Yong, Seok Hoon Jeong, and Yunsop Chong Department of Laboratory Medicine, Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea. Received: June 8, 2011Corresponding author: Dr. Yunsop Chong,Department of Laboratory Medicine,Research Institute of Bacterial Resistance,Yonsei University College of Medicine,50 Yonsei-ro, Seodaemun-gu,Seoul 120-752, Korea.Tel: 82-2-2228-2446, Fax: 82-2-313-0908E-mail: [email protected]∙ The authors have no financial conflicts ofinterest. Pathogenic bacteria have increasingly been resisting to antimicrobial therapy. Re-cently, resistance problem has been relatively much worsened in Gram-negativebacilli. Acinetobacter spp. are typical nosocomial pathogens causing infectionsand high mortality, almost exclusively in compromised

Antibiotics in the treatment of community-acquired and nosocomial pneumonia

Empirical antibiotic treatment for community-acquired pneumonia and accuracy for Legionella pneumophila, Mycoplasma pneumoniae, and Clamydophila pneumoniae: a descriptive cross-sectional study of adult patients in the emergency department Abstract Background Many factors determine empirical antibiotic treatment of community-acquired pneumonia (CAP). We aimed to describe the empirical antibiotic treatment CAP patients with an acute hospital visit and to determine if the current treatment algorithm provided specific and sufficient coverage against Legionella pneumophila, Mycoplasma pneumoniae, and Clamydophila pneumoniae (LMC). Methods A descriptive cross-sectional, multicenter study of all adults with an acute hospital visit in the Region of Southern Denmark between January 2016 and

EU Drug Approval Process

Introduction:   The EU drug approval system includes several routes that pharmaceutical companies can utilize to get their products approved across the 27 member states. These pathways are designed to accommodate the diverse nature of medicinal products and their intended uses:   Centralised Procedure (CP) Mutual Recognition Procedure (MRP) Decentralised Procedure (DCP)     Centralised Procedure (CP):   The Centralised Procedure is the process used by the European Medicines Agency (EMA) for the evaluation and approval of medicines for human and veterinary use, intended to be marketed within the European Union. Here’s a breakdown of the three main steps:   Step

CPIC® Guideline for Pharmacogenetics-Guided Warfarin Dosing

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update (December 2016) Updates since publication: No updates on dosing recommendations since this publication. Figures provided in the main manuscript of the guideline: Figure 1. Schematic representation of warfarin metabolism and its mechanism of action. Figure 2. Dosing recommendations for warfarin dosing based on genotype for adult patients Figure 3. Dosing recommendations for warfarin dosing based on genotype for pediatric patients Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update Tables provided in the guideline publication supplement or referenced in